Navigation Links
PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
Date:2/3/2009

encouraged rapid identification of eligible candidates for this important study," said Richard Finkel, MD, attending physician, director of the neuromuscular program, Children's Hospital of Philadelphia. "The completion of this trial enrollment is a striking example of the successes we can achieve when patients, families and the medical community come together to address an area of such high unmet medical need."

"Currently available therapies for nmDMD/BMD may alleviate the symptoms of this progressive debilitating disease, but none address the underlying cause of the disease." said Langdon Miller, MD, chief medical officer of PTC. "Ataluren represents a potential breakthrough as the first treatment designed to enable the formation of functioning dystrophin, the missing protein in patients with nmDMD/BMD."

This is the first pivotal trial for ataluren. In addition, PTC is conducting an open-label, long-term safety study in boys with nmDMD who participated in an early Phase 2a trial. PTC also plans to initiate a second pivotal clinical trial of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) in 2009.

The United States Adopted Names Council (USAN) in conjunction with the World Health Organization, International Nonproprietary Names Committee deemed ataluren's mechanism of action to be significantly novel, warranting creation of a new stem, -luren, for pharmaceuticals that are inducers of ribosomal readthrough of nonsense mutation mRNA stop codons.

"We are pleased to have completed enrollment of our first pivotal study of ataluren in boys and young men with nmDMD/BMD. To have achieved this milestone so far ahead of schedule is a tremendous achievement and we are grateful to the investigators, study coordinators, and the patients and their families for their efforts," said Stuart W. Peltz, PhD, president and CEO, PTC Therapeutics. "We look forward to completing this study ove
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
2. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
3. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
4. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
7. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
8. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
9. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and ... Interconnects and Packaging (EMIP) Division. "I am ... general management and business development experience, especially in the ... important contributions to the continued growth and success of ...
(Date:7/25/2014)... , July 25, 2014 Leading ... is returning for the seventh year to São Paulo, ... 7 th August 2014. The event will co-locate with ... most comprehensive meeting point for the pharmaceutical industry. ... top 25 countries for pharmaceutical sales are now exploring the ...
(Date:7/25/2014)... July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... corporate update and report second quarter 2014 financial results ... August 1, 2014. That same day, Arena will host ... Time (5:30 a.m. Pacific Time). The ... domestic callers and 914.495.8552 for international callers. Please specify ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... Nov. 4 HeartWare International, Inc. (Nasdaq: HTWR ... less invasive, miniaturized circulatory support technologies revolutionizing the treatment ... in revenues to $7.5 million for the third quarter ... million in revenues in the second quarter ended June ...
... , THOUSAND OAKS, Calif., Nov. 4 Amgen (Nasdaq: ... applications for its 19th annual Amgen Award for Science ... recognize and honor extraordinary science teachers at the K-12 ... teaching and who achieve demonstrated results in student learning ...
Cached Medicine Technology:HeartWare International Reports Third Quarter Revenues of $7.5 Million 2HeartWare International Reports Third Quarter Revenues of $7.5 Million 3HeartWare International Reports Third Quarter Revenues of $7.5 Million 4HeartWare International Reports Third Quarter Revenues of $7.5 Million 5HeartWare International Reports Third Quarter Revenues of $7.5 Million 6HeartWare International Reports Third Quarter Revenues of $7.5 Million 7Call for Applications: The Amgen Award for Science Teaching Excellence 2Call for Applications: The Amgen Award for Science Teaching Excellence 3
(Date:7/25/2014)... NC (PRWEB) July 25, 2014 Researchers at ... the results of a study indicating that a man-made material ... mesothelioma among workers exposed to asbestos. Surviving Mesothelioma has just ... to read it now. , The French scientists ... developed mesothelioma between 1987 and 2006. One group of ...
(Date:7/25/2014)... 25, 2014 Healthpointe is proud ... clinic is offering Occupational Medicine services to the ... accepting referrals and workers’ compensation cases. , ... clinic include wound care treatment management, return-to-work and ... pre-employment screening & physicals, and illness and injury ...
(Date:7/25/2014)... the leading pan-European association representing medical oncology professionals, ... Data Protection Regulation [1] could make cancer research ... doctors and cancer patients. , The proposed wording ... patient consent, meaning that researchers would have to ... in order to consult their data or use ...
(Date:7/25/2014)... Yisrayl Hawkins, Pastor and Overseer of The House of Yahweh ... revealing to the whole world, including even the most devout ... in his new article. , Yisrayl says it all started ... by the Catholic Church. He says this plan included removing ... and replacing it with titles such as Lord and God. ...
(Date:7/25/2014)... According to the Addict Him To You Pdf ... guide that teaches women how to get the love of ... its review that this book consists of 4 parts, including:, ... won’t commit yet (and what to do about it) , ... ,     Part 3: How to touch his heart ...
Breaking Medicine News(10 mins):Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Healthpointe Offering Occupational Medicine Services in La Mirada 2Health News:Is Europe putting cancer research at risk? 2Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3
... -- A program that helps elementary school students develop ... science and cultural studies may be one way to ... United States. In a new study, researchers assessed ... in which students explore, prepare and enjoy fresh, affordable ...
... 2011 A two-year study of patients in the ... (TAVR) in patients who have severe aortic stenosis and ... one-year findings and support the role of TAVR as ... today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... NOVEMBER 10, 2011 Results of the PARTNER ... replacement (TAVR) results in improved quality of life compared ... the transfemoral approach. The results of the study were ... (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. ...
... thinking about Parkinson,s disease is that it,s a disorder of ... brain,s substantia nigra to die or become impaired. A study ... a hereditary form of Parkinson,s disease cause mitochondria to run ... to stop them. Findings appear in the November 11 issue ...
... physicians for increasing the volume of visits and procedures ... health outcomes," the American College of Physicians (ACP) today ... Pensions (HELP) in a hearing on Improving Quality, Lowering ... does not provide incentives for physicians to coordinate care; ...
... News) -- All the color variations seen in prehistoric ... populations, which indicates that the ancient human artists accurately ... The research is also the first to provide ... Previous DNA studies produced evidence only for bay (reddish ...
Cached Medicine News:Health News:Cooking Class Benefits Kids in Many Ways 2Health News:Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011 2Health News:Quality of life benefits of transcatheter aortic valve replacement differ by access site 2Health News:Why do neurons die in Parkinson's disease? 2Health News:Internists express strong support for ACA's programs to support coordinated care 2Health News:Cave Art Accurately Depicted Horses of Different Colors 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: